ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors
BARCELONA / CAMBRIDGE, MA
Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today announced the appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as independent directors to the company’s Board of Directors, effective November 3, 2015.